Annual banned-substance review: Analytical approaches in human sports drug testing

Drug Testing and Analysis

Volumn 4, Issue 1, 2012, Pages 2-16

  Thevis, Mario ^a,b   Kuuranne, Tiia ^c   Geyer, Hans ^a   Schänzer, Wilhelm ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b European Monitoring Center for Emerging Doping Agents   (Germany)

^c United Medix Laboratories   (Finland)

Author keywords

Anabolic; Analysis; Blood; Doping; Drugs; Sport

Indexed keywords

CONTROLLED DRUG DELIVERY;

ANABOLIC; ANALYSE; ANALYTICAL APPROACH; BANNED SUBSTANCES; BLOOD; DOPING CONTROL; DRUG; DRUG TESTING; PERFORMANCE; WORLD ANTI-DOPING AGENCY;

SPORTS;

4' METHYLMETHCATHINONE; ANABOLIC AGENT; ANDROSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANNABINOID; CHORIONIC GONADOTROPIN; CLENBUTEROL; CORTICOTROPIN; EPITESTOSTERONE; ETIOCHOLANOLONE; GLUCOCORTICOID; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; HELIUM; NANDROLONE; NARCOTIC AGENT; PHOSPHODIESTERASE VII; PRASTERONE; RALOXIFENE; SALBUTAMOL; SOMATOMEDIN C; TAMOXIFEN; TESTOSTERONE; TOREMIFENE; ZERANOL;

ACCURACY; COMBUSTION; COST EFFECTIVENESS ANALYSIS; DOPING; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG URINE LEVEL; DRUG USE; ELECTROSPRAY MASS SPECTROMETRY; GAS CHROMATOGRAPHY; GENE THERAPY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOTOPE RATIO MASS SPECTROMETRY; KIDNEY CONCENTRATING CAPACITY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MASS FRAGMENTOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MICROWAVE IRRADIATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID PHASE EXTRACTION; SPECTROMETRY; TANDEM MASS SPECTROMETRY;

EID: 84856386085     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.415     Document Type: Review

References (107)

1. World Anti-Doping Agency. The 2011 Prohibited List. Available at: [27 October 2010].
2. A. M. Bellinger, S. Reiken, M. Dura, P. W. Murphy, S. X. Deng, D. W. Landry, D. Nieman, S. E. Lehnart, M. Samaru, A. LaCampagne, A. R. Marks Remodeling of ryanodine receptor complex causes 'leaky' channels: A molecular mechanism for decreased exercise capacity. P. Natl Acad. Sci. USA 2008, 105, 2198.
3. L. Yan, V. J. Colandrea, J. J. Hale Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia. Expert Opin. Ther. Pat. 2010, 20, 1219.
4. M. Thevis, T. Kuuranne, H. Geyer, W. Schänzer Annual banned-substance review: Analytical approaches in human sports drug testing. Drug Test. Analysis 2011, 3, 1.
5. M. Thevis, A. Thomas, W. Schänzer Current role of LC-MS(/MS) in doping control. Anal. Bioanal. Chem. 2011, 401, 405.
6. M. Thevis, A. Thomas, M. Kohler, S. Beuck, I. Möller, M. Schäfer, G. Rodchenkov, S. Yin, J. A. Loo, H. Geyer, W. Schänzer Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis. Eur. J. Mass. Spectrom. 2010, 16, 301.
7. 2+-Channel stabilizer S-107 and its implementation into routine doping control. Rapid Commun. Mass Spectrom. 2009, 23, 2363.
8. M. Thevis, S. Beuck, A. Thomas, M. Kohler, N. Schlörer, I. Vajiala, W. Schänzer Screening for the calstabin-ryanodine-receptor complex stabilizers JTV-519 and S-107 in doping control analysis. Drug Test. Analysis 2009, 1, 32.
9. S. Beuck, W. Schänzer, M. Thevis Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes. J. Mass Spectrom. 2011, 46, 112.
10. World Anti-Doping Agency. Laboratory Statistics 2010. Available at: [22 September 2011].
11. J. A. Munoz-Guerra, P. Prado, S. V. Garcia-Tenorio Use of hydrogen as a carrier gas for the analysis of steroids with anabolic activity by gas chromatography-mass spectrometry. J. Chromatogr. A 2011, 1218, 7365.
12. P. Van Eenoo, W. Van Gansbeke, N. De Brabanter, K. Deventer, F. T. Delbeke A fast, comprehensive screening method for doping agents in urine by gas chromatography-triple quadrupole mass spectrometry. J. Chromatogr. A 2011, 1218, 3306.
13. World Anti-Doping Agency. Minimum Required Performance Levels for Detection of Prohibited Substances. Available at: [26 October 2010].
14. M. Galesio, M. Mazzarino, X. de la Torre, F. Botre, J. L. Capelo Accelerated sample treatment for screening of banned doping substances by GC-MS: Ultrasonication versus microwave energy. Anal. Bioanal. Chem. 2011, 399, 861.
15. B. W. Jeon, H. H. Yoo, E. S. Jeong, H. J. Kim, C. Jin, D. H. Kim, J. Lee LC-ESI/MS/MS method for rapid screening and confirmation of 44 exogenous anabolic steroids in human urine. Anal. Bioanal. Chem. 2011, 401, 1353.
16. O. J. Pozo, P. Van Eenoo, K. Deventer, H. Elbardissy, S. Grimalt, J. V. Sancho, F. Hernandez, R. Ventura, F. T. Delbeke Comparison between triple quadrupole, time of flight and hybrid quadrupole time of flight analysers coupled to liquid chromatography for the detection of anabolic steroids in doping control analysis. Anal. Chim. Acta 2011, 684, 98.
17. U. Mareck, H. Geyer, G. Fussholler, A. Schwenke, N. Haenelt, T. Piper, M. Thevis, W. Schanzer Reporting and managing elevated testosterone/epitestosterone ratios-novel aspects after five years' experience. Drug Test. Analysis 2010, 2, 637.
18. R. S. Nicolich, M. C. Padilha, F. R. de Aquino Neto Study of the endogenous steroid profile of male athletes from the Brazilian National Soccer Championship 2009. Drug Test. Analysis 2010, 2, 599.
19. P. Van Renterghem, P. Van Eenoo, P. E. Sottas, M. Saugy, F. Delbeke A pilot study on subject-based comprehensive steroid profiling: Novel biomarkers to detect testosterone misuse in sports. Clin. Endocrinol. 2011, 75, 134.
20. P. Van Renterghem, P. Van Eenoo, P. E. Sottas, M. Saugy, F. Delbeke Subject-based steroid profiling and the determination of novel biomarkers for DHT and DHEA misuse in sports. Drug Test. Analysis 2010, 2, 582.
21. F. Badoud, E. Grata, J. Boccard, D. Guillarme, J. L. Veuthey, S. Rudaz, M. Saugy Quantification of glucuronidated and sulfated steroids in human urine by ultra-high pressure liquid chromatography quadrupole time-of-flight mass spectrometry. Anal. Bioanal. Chem. 2011, 400, 503.
22. L. Ekström, J. J. Schulze, C. Guillemette, A. Belanger, A. Rane Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene. Pharm. GKB 2011, 21, 325.
23. M. Mazzarino, M. G. Abate, R. Alocci, F. Rossi, R. Stinchelli, F. Molaioni, X. de la Torre, F. Botre Urine stability and steroid profile: towards a screening index of urine sample degradation for anti-doping purpose. Anal. Chim. Acta 2011, 683, 221.
24. T. Piper, C. Emery, M. Saugy Recent developments in the use of isotope ratio mass spectrometry in sports drug testing. Anal. Bioanal. Chem. 2011, 401, 433.
25. X. de la Torre, C. Colamonici, D. Curcio, F. Molaioni, M. Pizzardi, F. Botre A simplified procedure for GC/C/IRMS analysis of underivatized 19-norandrosterone in urine following HPLC purification. Steroids 2011, 76, 471.
26. M. K. Kioussi, Y. S. Angelis, A. T. Cawley, M. Koupparis, R. Kazlauskas, J. T. Brenna, C. G. Georgakopoulos External calibration in gas chromatography-combustion-isotope ratio mass spectrometry measurements of endogenous androgenic anabolic steroids in sports doping control. J. Chromatogr. A 2011, 1218, 5675.
27. E. Munton, J. Murby, D. B. Hibbert, R. Santamaria-Fernandez Systematic comparison of delta13C measurements of testosterone and derivative steroids in a freeze-dried urine candidate reference material for sports drug testing by gas chromatography/combustion/isotope ratio mass spectrometry and uncertainty evaluation using four different metrological approaches. Rapid Commun. Mass Spectrom. 2011, 25, 1641.
28. 12C ratios of endogenous urinary steroids after pregnenolone administration. Drug Test. Analysis 2011, 3, 283.
29. M. Thevis, H. Geyer, A. Thomas, W. Schänzer Trafficking of drug candidates relevant for sports drug testing: Detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the Internet. Drug Test. Analysis 2011, 3, 331.
30. M. Thevis, E. Gerace, A. Thomas, S. Beuck, H. Geyer, N. Schlörer, J. D. Kearbey, J. T. Dalton, W. Schänzer Characterization of in vitro generated metabolites of the selective androgen receptor modulators S-22 and S-23 and in vivo comparison to post-administration canine urine specimens. Drug Test. Analysis 2010, 2, 589.
31. M. Thevis, A. Thomas, I. Möller, H. Geyer, J. T. Dalton, W. Schänzer Mass spectrometric characterization of urinary metabolites of the selective androgen receptor modulator S-22 to identify potential targets for routine doping controls. Rapid Commun. Mass Spectrom. 2011, 25, 2187.
32. M. K. Parr, G. Opfermann, H. Geyer, F. Westphal, F. D. Sonnichsen, J. Zapp, D. Kwiatkowska, W. Schanzer Seized designer supplement named '1-Androsterone': identification as 3beta-hydroxy-5alpha-androst-1-en-17-one and its urinary elimination. Steroids 2011, 76, 540.
33. M. K. Parr, G. Fussholler, N. Schlorer, G. Opfermann, H. Geyer, G. Rodchenkov, W. Schanzer Detection of Delta6-methyltestosterone in a 'dietary supplement' and GC-MS/MS investigations on its urinary metabolism. Toxicol. Lett. 2011, 201, 101.
34. S. Wolf, P. Diel, M. K. Parr, F. Rataj, W. Schänzer, G. Vollmer, O. Zierau Long-term detection of methyltestosterone (ab-) use by a yeast transactivation system. Arch. Toxicol. 2011, 85, 285.
35. H. G. Brown, D. Perrett Detection of doping in sport: detecting anabolic-androgenic steroids in human fingernail clippings. Med. Leg. J. 2011, 79, 67.
36. J. W. Fisher Landmark advances in the development of erythropoietin. Exp. Biol. Med. 2010, 235, 1398.
37. G. Gmeiner, C. Reichel, R. Kulovics, V. Scheiblhofer Defending Dynepo detection. Drug Test. Analysis 2010, 2, 526.
38. C. Reichel Recent developments in doping testing for erythropoietin. Anal. Bioanal. Chem. 2011, 401, 463.
39. C. Tsitsimpikou, D. Kouretas, K. Tsarouhas, K. Fitch, D. A. Spandidos, A. Tsatsakis Applications and biomonitoring issues of recombinant erythropoietins for doping control. Ther. Drug Monit. 2011, 33, 3.
40. C. Reichel Practicing IEF-PAGE of EPO: the impact of detergents and sample application methods on analytical performance in doping control. Drug Test. Analysis 2010, 2, 603.
41. F. Lasne, L. Martin, J.-A. Martin Cave digitabula. Electrophoresis 2011, 32, 1444.
42. C. Reichel, E. Benetka, T. Geisendorfer, V. Scheiblhofer, F. Abzieher The interference of heparin on IEF-PAGE of erythropoietins. Drug Test. Analysis 2010, 2, 568.
43. Y. Dehnes, S. Lamon, M. Lönnberg Erythropoietin (EPO) immunoaffinity columns-A powerful tool for purifying EPO and its recombinant analogues. J. Pharm. Biomed. Anal. 2010, 53, 1028.
44. M. Lönnberg, Y. Dehnes, M. Drevin, M. Garle, S. Lamon, N. Leuenberger, T. Quach, J. Carlsson Rapid affinity purification of erythropoietin from biological samples using disposable monoliths. J. Chromatogr. A 2010, 1217, 7031.
45. Y. Dehnes, P. Hemmersbach Effect of single doses of methoxypolyethylene glycol-epoetin beta (CERA, Mircera) and epoetin delta (Dynepo) on isoelectric erythropoietin profiles and haematological parameters. Drug Test. Analysis 2011, 3, 291.
46. I. Möller, A. Thomas, H. Geyer, W. Schänzer, M. Thevis Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes. Rapid Commun. Mass Spectrom. 2011, 25, 2115.
47. B. Christensen, L. Sackmann-Sala, D. Cruz-Topete, J. O. Jorgensen, N. Jessen, C. Lundby, J.J. Kopchick Novel serum biomarkers for erythropoietin use in humans: A proteomic approach. J. Appl. Physiol. 2011, 110, 149.
48. W. Jelkmann, C. Lundby Blood doping and its detection. Blood 2011, 118, 2395.
49. P. E. Sottas, N. Robinson, O. Rabin, M. Saugy The athlete biological passport. Clin. Chem. 2011, 57, 969.
50. N. Robinson, M. Saugy, A. Vernec, P. E. Sottas The athlete biological passport: An effective tool in the fight against doping. Clin. Chem. 2011, 57, 830.
51. M. Zorzoli The Athlete Biological Passport from the perspective of an anti-doping organization. Clin. Chem. Lab. Med. 2011, 49, 1423.
52. E. Callaway Sports doping: Racing just to keep up. Nature 2011, 475, 283.
53. M. Zorzoli, F. Rossi Implementation of the biological passport: The experience of the International Cycling Union. Drug Test. Analysis 2010, 2, 542.
54. G. Banfi Limits and pitfalls of athlete's biological passport. Clin. Chem. Lab. Med. 2011, 49, 1417.
55. F. Sanchis-Gomar, V. E. Martinez-Bello, M. C. Gomez-Cabrera, J. Vina Current limitations of the Athlete's Biological Passport use in sports. Clin. Chem. Lab. Med. 2011, 49, 1413.
56. Y. O. Schumacher, D. Sahm, M. W. Baumstark, T. Pottgiesser Reticulocytes in athletes: Longitudinal aspects and the influence of long- and short-term exercise. Drug Test. Analysis 2010, 2, 469.
57. Y. O. Schumacher, T. Pottgiesser The impact of acute gastroenteritis on haematological markers used for the athletes biological passport - report of 5 cases. Int. J. Sports Med. 2011, 32, 147.
58. M. Ashenden, C. E. Gough, A. Garnham, C. J. Gore, K. Sharpe Current markers of the Athlete Blood Passport do not flag microdose EPO doping. Eur. J. Appl. Physiol. 2011, 111, 2307.
59. T. Pottgiesser, P. E. Sottas, T. Echteler, N. Robinson, M. Umhau, Y. O. Schumacher Detection of autologous blood doping with adaptively evaluated biomarkers of doping: A longitudinal blinded study. Transfusion 2011, 51, 1707.
60. J. Morkeberg, K. Sharpe, B. Belhage, R. Damsgaard, W. Schmidt, N. Prommer, C. J. Gore, M. J. Ashenden Detecting autologous blood transfusions: A comparison of three passport approaches and four blood markers. Scand. J. Med. Sci. Sports 2011, 21, 235.
61. P. E. Sottas, N. Robinson, G. Fischetto, G. Dolle, J. M. Alonso, M. Saugy Prevalence of blood doping in samples collected from elite track and field athletes. Clin. Chem. 2011, 57, 762.
62. M. Tsivou, D. G. Georgakopoulos, H. A. Dimopoulou, M. A. Koupparis, J. Atta-Politou, C. G. Georgakopoulos Stabilization of human urine doping control samples: A current opinion. Anal. Bioanal. Chem. 2011, 401, 553.
63. M. Tsivou, H. A. Dimopoulou, D. G. Georgakopoulos, M. A. Koupparis, J. Atta-Politou, C. G. Georgakopoulos Stabilization of human urine doping control samples: IV. Human chorionic gonadotropin. Anal. Bioanal. Chem. 2010, 398, 1313.
64. V. Birzniece, A. E. Nelson, K. K. Ho Growth hormone and physical performance. Trends Endocrinol. Metab. 2011, 22, 171.
65. R. I. Holt Detecting growth hormone abuse in athletes. Anal. Bioanal. Chem. 2011, 401, 449.
66. K. K. Ho, A. E. Nelson Growth hormone in sports: Detecting the doped or duped. Horm. Res. Paediatr. 2011, 76(1), 84.
67. S. Pichini, R. Ventura, I. Palmi, S. di Carlo, A. Bacosi, K. Langohr, R. Abellan, J. A. Pascual, R. Pacifici, J. Segura, P. Zuccaro Effect of physical fitness and endurance exercise on indirect biomarkers of growth hormone and insulin misuse: Immunoassay-based measurement in urine samples. J. Pharm. Biomed. Anal. 2010, 53, 1003.
68. J. G. Bruno, M. P. Carrillo, T. Phillips, A. Edge Discrimination of recombinant from natural human growth hormone using DNA aptamers. J. Biomol. Tech. 2011, 22, 27.
69. M. Okano, Y. Nishitani, M. Sato, A. Ikekita, S. Kageyama Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: Growth hormone isoform profiles in Japanese male subjects. Drug Test. Analysis 2010, 2, 548.
70. A. Thomas, S. Hoppner, H. Geyer, W. Schänzer, M. Petrou, D. Kwiatkowska, A. Pokrywka, M. Thevis Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry. Anal. Bioanal. Chem. 2011, 401, 507.
71. J. Henninge, M. Pepaj, I. Hullstein, P. Hemmersbach Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test. Analysis 2010, 2, 647.
72. A. Chaabo, J. de Ceaurriz, C. Buisson, J. C. Tabet, F. Lasne Simultaneous quantification and qualification of synacthen in plasma. Anal. Bioanal. Chem. 2011, 399, 1835.
73. B. M. Pluim, O. de Hon, J. B. Staal, J. Limpens, H. Kuipers, S. E. Overbeek, A. H. Zwinderman, R. J. Scholten beta-Agonists and physical performance: A systematic review and meta-analysis of randomized controlled trials. Sports Med. 2011, 41, 39.
74. J. Elers, L. Pedersen, V. Backer Asthma in elite athletes. Expert Rev. Respir. Med. 2011, 5, 343.
75. K. M. Lee, H. J. Kim, E. S. Jeong, H. H. Yoo, O. S. Kwon, C. Jin, D. H. Kim, J. Lee Simple and accurate quantitative analysis of seven prohibited threshold substances in human urine by liquid chromatography/tandem mass spectrometry in doping control. Rapid Commun. Mass Spectrom. 2011, 25, 2261.
76. J. Elers, L. Pedersen, J. Henninge, P. Hemmersbach, K. Dalhoff, V. Backer Urine concentrations of repetitive doses of inhaled salbutamol. Int. J. Sports Med. 2011, 32, 574.
77. T. Trdan, R. Roskar, J. Trontelj, M. Ravnikar, A. Mrhar Determination of raloxifene and its glucuronides in human urine by liquid chromatography-tandem mass spectrometry assay. J. Chromatogr. B 2011, 879, 2323.
78. M. Mazzarino, X. de la Torre, F. Botre Urinary excretion profiles of toremifene metabolites by liquid chromatography-mass spectrometry. Towards targeted analysis to relevant metabolites in doping control. Anal. Bioanal. Chem. 2011, 401, 529.
79. C. Gomez, O. J. Pozo, R. Diaz, J. V. Sancho, E. Vilaroca, J. P. Salvador, M.P. Marco, F. Hernandez, J. Segura, R. Ventura Mass spectrometric characterization of urinary toremifene metabolites for doping control analyses. J. Chromatogr. A 2011, 1218, 4727.
80. J. Lu, X. Wang, Y. Xu, Y. Dong, S. Yang, Y. Wu, Y. Qin, M. Wu Mass spectrometric characterization of toremifene metabolites in human urine by liquid chromatography-tandem mass spectrometry with different scan modes. Analyst 2011, 136, 467.
81. A. Cavalcanti Gde, B. C. Garrido, F. D. Leal, M. C. Padilha, X. de la Torre, H. M. Pereira, F. R. de Aquino Neto Analysis of exemestane and 17beta-hydroxyexemestane in human urine by gas chromatography/mass spectrometry: Development and validation of a method using MO-TMS derivatives. Rapid Commun. Mass Spectrom. 2010, 24, 3297.
82. P. Diel, T. Schiffer, S. Geisler, T. Hertrampf, S. Mosler, S. Schulz, K. F. Wintgens, M. Adler Analysis of the effects of androgens and training on myostatin propeptide and follistatin concentrations in blood and skeletal muscle using highly sensitive immuno PCR. Mol. Cell. Endocrinol. 2010, 330, 1.
83. M. Mazzarino, F. De Angelis, T. Di Cicco, X. de la Torre, F. Botre Microwave irradiation for a fast gas chromatography-mass spectrometric analysis of polysaccharide-based plasma volume expanders in human urine. J. Chromatogr. B 2010, 878, 3024.
84. M. Kolmonen, A. Leinonen, T. Kuuranne, A. Pelander, K. Deventer, I. Ojanpera Specific screening method for dextran and hydroxyethyl starch in human urine by size exclusion chromatography-in-source collision-induced dissociation-time-of-flight mass spectrometry. Anal. Bioanal. Chem. 2011, 401, 563.
85. F. Schifano, A. Albanese, S. Fergus, et al. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology 2011, 214, 593.
86. G. De Paoli, P. D. Maskell, D. J. Pounder Naphyrone: Analytical profile of the new "legal high" substitute for mephedrone. J. Forensic Leg. Med. 2011, 18, 93.
87. K. Deventer, K. Roels, F. T. Delbeke, P. Van Eenoo Prevalence of legal and illegal stimulating agents in sports. Anal. Bioanal. Chem. 2011, 401, 421.
88. S. D. Brandt, S. Freeman, H. R. Sumnall, F. Measham, J. Cole Analysis of NRG 'legal highs' in the UK: Identification and formation of novel cathinones. Drug Test. Analysis 2011, 3, 569.
89. S. D. Brandt, R. C. Wootton, G. De Paoli, S. Freeman The naphyrone story: The alpha or beta-naphthyl isomer? Drug Test. Analysis 2010, 2, 496.
90. P. I. Dargan, R. Sedefov, A. Gallegos, D. M. Wood The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test. Analysis 2011, 3, 454.
91. D. M. Wood, S. L. Greene, P. I. Dargan Clinical pattern of toxicity associated with the novel synthetic cathinone mephedrone. Emerg. Med. J. 2011, 28, 280.
92. J. P. Kelly Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test. Analysis 2011, 3, 439.
93. R. P. Archer, R. Treble, K. Williams Reference materials for new psychoactive substances. Drug Test. Analysis 2011, 3, 505.
94. P. D. Sainsbury, A. T. Kicman, R. P. Archer, L. A. King, R. A. Braithwaite Aminoindanes-the next wave of 'legal highs'? Drug Test. Analysis 2011, 3, 479.
95. H. Torrance, G. Cooper The detection of mephedrone (4-methylmethcathinone) in 4 fatalities in Scotland. Forensic Sci. Int. 2010, 202, e62.
96. C. Bell, C. George, A. T. Kicman, A. Traynor Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs. Drug Test. Analysis 2011, 3, 496.
97. N. Gray, A. Musenga, D. A. Cowan, R. Plumb, N. W. Smith A simple high pH liquid chromatography-tandem mass spectrometry method for basic compounds: Application to ephedrines in doping control analysis. J. Chromatogr. A 2011, 1218, 2098.
98. M. Thevis, G. Sigmund, V. Gougoulidis, S. Beuck, N. Schlörer, A. Thomas, D. Kwiatkowska, A. Pokrywka, W. Schänzer Screening for benfluorex and its major urinary metabolites in routine doping controls. Anal. Bioanal. Chem. 2011, 401, 543.
99. V. F. Sardela, P. D. Sardela, H. M. Pereira, F. R. Aquino Neto Consequences of the formation of 3, 4-dimethyl-5-phenyl-1, 3-oxazolidine on the analysis of ephedrines in urine by gas chromatography and a new method for confirmation as N-trifluoroacetyl-O-t-butyldimethylsilyl ether derivatives. J. Chromatogr. A 2011, 1218, 1266.
100. I. Möller, A. Wintermeyer, K. Bender, M. Jübner, A. Thomas, O. Krug, W. Schänzer, M. Thevis Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls. Drug Test. Analysis 2011, 3, 609.
101. S. Beuck, I. Möller, A. Thomas, A. Klose, N. Schlörer, W. Schänzer, M. Thevis Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesized reference material for the support of LC-MS/MS-based drug testing. Anal. Bioanal. Chem. 2011, 401, 493.
102. E. Solymos, S. Guddat, H. Geyer, U. Flenker, A. Thomas, J. Segura, R. Ventura, P. Platen, M. Schulte-Mattler, M. Thevis, W. Schänzer Rapid determination of urinary di(2-ethylhexyl) phthalate metabolites based on liquid chromatography/tandem mass spectrometry as a marker for blood transfusion in sports drug testing. Anal. Bioanal. Chem. 2011, 401, 517.
103. F. Mingozzi, K. A. High Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges. Nat. Rev. Genet. 2011, 12, 341.
104. B. L. Davidson, P. B. McCray Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 2011, 12, 329.
105. T. Beiter, M. Zimmermann, A. Fragasso, J. Hudemann, A. M. Niess, M. Bitzer, U. M. Lauer, P. Simon Direct and long-term detection of gene doping in conventional blood samples. Gene Ther. 2011, 18, 225.
106. W. Ni, C. Le Guiner, G. Gernoux, M. Penaud-Budloo, P. Moullier, R. O. Snyder Longevity of rAAV vector and plasmid DNA in blood after intramuscular injection in nonhuman primates: Implications for gene doping. Gene Ther. 2011, 18, 709.
107. S. Scarano, M. L. Ermini, M. M. Spiriti, M. Mascini, P. Bogani, M. Minunni Simultaneous detection of transgenic DNA by surface plasmon resonance imaging with potential application to gene doping detection. Anal. Chem. 2011, 83, 6245.